Ascentage Pharma Group International
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASPHF research report →
Price Chart
About the company
Ascentage Pharma Group International is a clinical-stage biopharmaceutical firm dedicated to discovering and developing innovative therapies for various cancers, chronic hepatitis B virus (HBV), and age-related conditions. Its operations are concentrated across the United States and Mainland China. Ascentage Pharma's flagship therapeutic candidate, HQP1351 (Olverembatinib), is a BCR-ABL inhibitor specifically designed to target BCR-ABL mutants, including those carrying the T315I mutation.
- CEO
- Dajun Yang
- IPO
- 2021
- Employees
- 767
- HQ
- Suzhou, JS, CN
Get TickerSpark's AI analysis on ASPHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $1.29B
- P/E
- -5.11
- Fwd P/E
- 4.10
- PEG
- 0.50
- P/S
- 11.73
- P/B
- 13.34
- EV/EBITDA
- -5.87
- Div Yield
- 0.00%
- Gross Margin
- 81.56%
- Op Margin
- -218.70%
- Net Margin
- -228.60%
- ROE
- -153.78%
- ROIC
- -48.87%
Latest fiscal year · YoY change
- Revenue
- $559.30M-43.0%
- Gross Profit
- $427.38M-55.1%
- Op Income
- $-1,180,905,484
- Net Income
- $-1,210,698,288-198.6%
- EPS
- $-3.43-150.4%
- OCF Growth
- -954.4%
- FCF Growth
- -785.9%
- 52W High
- $8.48
- 52W Low
- $3.46
- 50D MA
- $3.88
- 200D MA
- $5.74
- Beta
- 0.66
- RSI (14)
- 0
- Avg Volume
- 191
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ascentage reported 29% revenue growth, reaffirmed cash runway through 2027, and said multiple global registration trials are on track for potential NDA filings in the second half of next year.· August 20, 2026
- Total revenue was $44.5 million, up 29.3% year over year; product sales were $41.6 million.
- Cash was $279.4 million at June 30, 2026, and management reaffirmed runway through the end of 2027.
- Enrollment in key global registrational studies is progressing, with GLORA-2 complete and GLORA-3 close; GLORA-4, POLARIS-1, and POLARIS-2 are expected to finish by late this year or early next year.
- Management said it is aiming for potential NDA filings in the second half of next year, with POLARIS-2 tied to a 6-month MMR endpoint and POLARIS-1 tied to a 3-month MRD-negative CR endpoint.
- The company highlighted ongoing China commercialization progress, including NRDL review for lisaftoclax and a plan to expand its China commercial force toward about 400 people and 2,000 hospitals.
Total revenue was $44.5 million in the first half of 2026 versus $32.6 million in the first half of 2025, up $11.9 million or 29.3% on a constant exchange rate basis. Product sales were $41.6 million. Research and development expense was $102.8 million versus $73.8 million a year ago, up $29.0 million or 32%; selling and distribution expense was $33.4 million versus $19.2 million, up $14.2 million or 64.3%; and administration expense was $17.5 million versus $13.9 million. Cash and cash equivalents were $279.4 million at June 30, 2026, and management reaffirmed cash runway through the end of 2027. Forward-looking commentary: GLORA-4, POLARIS-1 and POLARIS-2 are expected to complete enrollment by late this year or early next year, and management said it is looking for potential NDA filings in the second half of next year.
Dajun Yang framed the first half as progress toward making Ascentage a global, fully integrated hematology-oncology company. He emphasized that the company now has 2 approved products and 9 global registrational trials, with 4 cleared by both the FDA and EMA, and repeatedly highlighted differentiation from competitors on dosing convenience, safety, and resistance profiles. His tone was confident and expansive, with repeated references to the company becoming a global player and to multiple upcoming catalysts.
Veet Misra said the first half showed continued commercial growth alongside heavy investment in global development. He cited $44.5 million of total revenue, $41.6 million of product sales, R&D of $102.8 million, selling and distribution of $33.4 million, and administration expense of $17.5 million. He also said cash was $279.4 million at June 30, 2026, reaffirmed runway through 2027, and noted that spending is near peak as enrollment nears completion; he also said the company is keeping flexibility for capital raising and partnerships.
Analysts focused on lisaftoclax’s NRDL prospects in China, enrollment and timing for GLORA and POLARIS readouts, the Takeda option on olverembatinib, and whether APG-3288 could produce ASH data this year. Management said lisaftoclax has passed initial NRDL review and is on the final expert-review list, with a meeting possible later this month or early September, and said it is confident on coverage subject mainly to final price. For the pivotal trials, management said GLORA-2 is enrolled, GLORA-3 is close to complete, and GLORA-4, POLARIS-1, and POLARIS-2 are targeted to finish late this year or early next year, with potential NDA filings in the second half of next year. On 3288, they said no Phase I data are expected at ASH this year because the cutoff has passed.
The bull case from this call is that Ascentage now has two marketed hematology assets in China, a meaningful revenue base, and a pipeline with multiple late-stage shots on goal. Management believes lisaftoclax and olverembatinib are differentiated on dosing, safety, and efficacy, while cash runway through 2027 reduces near-term financing pressure.
The main risks are that the company is still burning heavily while running nine registrational studies, and commercial expansion outside China will require substantial execution and capital. Several milestones are still ahead: GLORA-4, POLARIS-1 and POLARIS-2 are not yet enrolled, APG-3288 will not have Phase I data at ASH this year, and lisaftoclax’s NRDL outcome still depends on final pricing and review.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 80.7%
- Shares Outstanding
- 373.17M
- Float Shares
- 301.19M
Our ASPHF coverage
Recent articles, reports, and earnings notes.
No research on ASPHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ASPHF report →Ascentage Pharma Group International (AAPG) Q4 2025 Earnings Call Transcript
seekingalpha.com · Mar 26
Ascentage Pharma Group International (AAPG) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
seekingalpha.com · Feb 12
Ascentage Pharma Group International (OTCMKTS:ASPHF) Sees Significant Increase in Short Interest
defenseworld.net · Jan 19
Ascentage Pharma Group International (AAPG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
seekingalpha.com · Jan 15
Ascentage Pharma Group International (OTCMKTS:ASPHF) Stock Price Down 23.4% – Should You Sell?
defenseworld.net · Nov 26
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update
defenseworld.net · Oct 30
Ascentage Pharma Group International (AAPG) Presents At Citi's Biopharma Back To School Conference Transcript
seekingalpha.com · Sep 3
Takeda-backed Ascentage Pharma aims to raise $126 mln in US IPO
reuters.com · Jan 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.